MITTEILUNG UEBERMITTELT VON BUSINESS WIRE. FUER DEN INHALT IST ALLEIN DAS BERICHTENDE UNTERNEHMEN VERANTWORTLICH.
- New platform powered by Opentrons expands lab automation to accelerate scientific discovery
- Plug-and-play design for effortless integration into diverse laboratory settings
- Verified protocols across applications benefit academia, pharma, and biotech
DARMSTADT, Germany --(BUSINESS WIRE)-- 15.07.2025 --
Merck, a leading science and technology company, has launched the AAWTM Automated Assay Workstation, a solution powered by Opentrons, a leader in lab automation and accessible robotics. The workstation automates routine laboratory experiments previously performed manually, reducing hands-on time and ensuring consistency in results across diverse experimental settings. This launch follows the earlier announcement of a multi-year partnership with Opentrons Labworks, Inc. to enhance laboratory workflows through automation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715183465/en/
"Our customers are increasingly seeking tools that improve efficiency and deliver reliable and reproducible results," said Anand Nambiar, Head of Science & Lab Solutions for the Life Science business sector of Merck. "The AAWTM platform exemplifies our commitment to equipping scientists with solutions that simplify their workflows and enhance their research capabilities. By automating routine tasks, researchers can focus on solving complex scientific challenges and accelerate discovery."
Designed to advance the lab of the future, the AAWTM platform offers a plug-and-play setup and an extensive library of verified assay protocols across protein, molecular, and cell biology applications. Its versatility and ease of integration make it an ideal fit for academic, biotech, and pharmaceutical labs looking to boost productivity without compromising quality.
The AAWTM platform joins Merck's growing portfolio of digital and automation innovations, including:
- M-Trace® Software: The first software offering complete data traceability in microbial QC.
- MyMilli-QTM Services: A digital platform for water purification system oversight, ensuring high-quality water for critical experiments.
- ChemisTwin® Platform: The first-ever digital reference material platform that confirms compound structures and quantifies samples.
For more information about the AAWTM platform and to explore our full range of innovative solutions, visit SigmaAldrich.com/AAW-Yeah.
About Merck
Merck, a leading science and technology company, operates across life science, healthcare and electronics. More than 62,000 employees work to make a positive difference to millions of people's lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices - the company is everywhere. In 2024, Merck generated sales of € 21.2 billion in 65 countries.
Scientific exploration and responsible entrepreneurship have been key to Merck's technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as MilliporeSigma in life science, EMD Serono in healthcare, and EMD Electronics in electronics.
All Merck press releases are distributed by e-mail at the same time they become available on the Merck website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.
About Opentrons
Opentrons Labworks, Inc., a disruptive life science company and the current market leader in entry-level lab automation, accelerates innovation in research and healthcare through its integrated lab platform, which includes business units Opentrons® Robotics and NeochromosomeTM. Opentrons has raised over $200 million in funding and achieved unicorn status based on its innovative technologies. The Opentrons Flex® is Opentrons' newest generation of liquid-handling lab robots, offering open-source accessibility and compatibility with generative AI tools. Opentrons Robotics provides thousands of institutions with flexible, easy-to-use lab robots, automating R&D operations and making robotics, a vast open-source library accessible to life sciences researchers worldwide. Opentrons is used in labs at the top 20 academic universities in the US and 14 of 15 leading global biopharmaceutical companies. Learn more at https://opentrons.com/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250715183465/en/
Media Relations
jenny.wuestner@merckgroup.com
Phone: +49 151 1454 3158
